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E. Buchel, R. J. Hift, T. Wilson,
S. S. Abdool Karim
The identification and characterisation of the hepatitis
viruses A, B, C, 0 and E has allowed greater insight into
their diagnosis, prevalence and modes of transmission.
The clinical, pathological and serological features of each of
these viruses have been dealt with elsewhere in this issue of
the SAMJ, as have general and specific measures required
for the prevention and future elimination of the diseases they
cause. A recent consensus statement defined the problem
posed by the hepatitis viruses in South Africa and
highlighted the measures necessary to manage this
effectively.' This article will concentrate on measures
designed to convey passive or active immunity to hepatitis A
and B. However, the importance of general measures for the
upliftment of underprivileged communities must constantly
be borne in mind since these play a vital role in reducing
infection, morbidity and mortality due to the hepatitis
viruses.
Hepatitis A virus (HAV)
General measures
Hepatitis A infection is spread by the faecal-oral route. In
developing countries 100% of the population have
antibodies against hepatitis A by age 20, whereas in
developed countries only 30 - 50% of the adult population
have evidence of previous exposure to the virus! The higher
incidence in developing countries is largely thought to be
due to poor housing, lack of clean water and inadequate
sewerage systems, and measures aimed at addressing
these inadequacies could be expected to reduce infection
by at least 50%. Travellers from developed countries should
avoid local drinking water, ice cubes, shellfish, salads and
uncooked food when visiting hyperendemic areas.3
Pre-exposure prophylaxis
The morbidity and mortality of hepatitis A is age-related. In
black South Africans infection with hepatitis A usually
occurs in childhood and is most often subclinical and
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anicteric. In white South Africans there is less infection in
childhood and more infection in older children and adults:
who often develop full-blown, icteric disease which
occasionally progresses to acute liver failure.
Passive immunisation
A major indication for pre-exposure passive immunisation
remains the protection of travellers to regions where
hepatitis A is hyperendemic.',6 The incidence of infection
with hepatitis A in unprotected travellers staying in
international hotels in hyperendemic areas is estimated to bf
3 - 6 cases/1 000 persons/month of stay. This increases to
20/1 000 for travellers eating and drinking in local
establishments. With the exception of hepatitis B, which has
a slightly higher mortality in expatriates, the morbidity and
mortality of hepatitis A is greater than for any other
preventable disease in travellers.?
Immune globulin (human immune serum globulin or
gamma-globulin) (IG) given by intramuscular injection will
protect against hepatitis for 4 - 6 months. Although
experience indicates that 0,02 ml/kg of IG protects as
adequately as larger doses," more recent recommendations
from the USA suggest a dose of 0,06 ml/kg.',6 This reflects
the decreasing titres of antibody in the donor pool from
which IG is prepared as the prevalence of hepatitis A
decreases in the developed world, IG prepared in South
Africa, where the disease prevalence is high, may be
used in lower doses - 0,02 - 0,04 ml/kg for contacts and
0,05 - 0,06 ml/kg for travellers to endemic areas, The advent
of a vaccine for hepatitis A should obviate the need for
repeated doses of IG, since frequent travellers or those who
intend spending more than 3 months in a hyperendemic
area should be vaccinated against this disease.
Vaccination against hepatitis A
Several vaccines have been developed against HAV. Of
these, Havrix (Smith Kline Beecham), a formaldehyde-
inactivated vaccine prepared from HAV, has been released in
South Africa. It is available as a 1 ml dose containing 720
ELlSA units of hepatitis A viral protein. The immunisation
schedule consists of two doses of 1 ml of vaccine, spaced 2
weeks to 1 month apart, given intramuscularly in the deltoid,
A booster dose is given 6 - 12 months after the initial dose.
This vaccination schedule is expected to provide immunity
for up to 10 years. In haemodialysis patients and those with
impaired immune systems adequate antibody titres may not
be obtained after the primary immunisation course, and
these patients may require additional booster doses. Havrix
can be administered simultaneously with IG, although they
should be injected at different sites. It is, however, not yet
clear whether active immunisation is efficacious for post-
exposure prophylaxis, and combining IG with the inactivated
vaccine appears to depress the level of antibody response
obtained.9 An additional booster dose of vaccine may
therefore be necessary. There appears to be no interference
in the immune response to both antigens when hepatitis B
vaccine is given concomitantly, although different injection
sites are advised. Havrix is an inactivated viral vaccine and
the risk to the fetus is considered negligible; however, it is
not yet recommended in pregnancy, The effect in breast-fed
infants has not yet been evaluated and it should therefore be
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used with caution in breast-feeding women. The vaccine
appears to be well tolerated. Mild transient soreness and
erythema at the injection site is the most common side-
effect, while general complaints of malaise and headache
are less common.'o
Pre-exposure vaccination is advised for non-immune
travellers to areas of high endemicity. This would include
Africa, the Middle and Far East, central and south America
and tropical islands. Workers in child care centres and in
mental institutions and non-immune health care personnel
should also consider vaccination. In order to prevent spread
of infection, food handlers and kitchen workers should be
considered for vaccination.
Mass vaccination of children, with appropriate boosters
once the period of immunity is known, will not only decrease
the morbidity and mortality due to HAV but will decrease the
infectious pool and with it the risk of contracting the
disease. Thus while routine immunisation of South Africans
against HAV may not be as urgent as immunisation against
the B virus, consideration should be given to including
vaccination against hepatitis A in routine vaccination
schedules."
Post-exp,?sure prophylaxis - passive
immunisation
Post-exposure hepatitis A prophylaxis is provided via a
single intramuscular dose of 0,02 ml/kg of the South African
IG preparation. Immunisation is appropriate under the
following circumstances:,,6
1. IG is recommended for all household and sexual
contacts of persons with hepatitis A
2. Day care centres, especially those attended by children
in nappies, are important sources of HAV transmission. IG
should be given to all staff and children as soon as an
outbreak is recognised; in practical terms this means when
hepatitis A is diagnosed in even a single child or employee,
or if the disease is recognised in the households of two or
more children attending the creche.
3. Contact at primary and secondary schools and at
colleges does not usually result in transmission of hepatitis
A. Propliylaxis is not usually necessary unless a classroom-
centred outbreak (hepatitis in 3 or more individuals) occurs,
in which case IG should be considered for contacts.
4. Living conditions in institutions such as prisons and
care facilities for the mentally disabled favour transmission
of hepatitis A When outbreaks occur IG should be given to
inmates and staff. Depending on the epidemiological
circumstances prophylaxis can be limited or can include the
entire institution. With the introduction of hepatitis A vaccine,
vaccination of non-immune staff should be considered.
5. Routine IG prophylaxis is not recommended for
hospital personnel. Paediatricians and nurses in children's
wards are invariably more exposed to hepatitis A and should
be vaccinated if they are not immune.
The earlier IG is given in the post-exposure period, the
more likely it is to have a protective effect. There is evidence
that the course of hepatitis A can be prevented or
attenuated by the administration of IG even after exposure
to the virus, provided this takes place at least 2 weeks
before the onset of jaundice.12
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Hepatitis B virus (HBV)
The transmission of HBV by transfusion or accidental
innoculation, during childbirth and through unprotected
sexual intercourse is discussed elsewhere in this issue of the
SAMJ. However, these do not explain the predominantly
horizontal transmission of this virus seen in southern Africa.'3
Indeed, the prevalence of markers of current or previous
infection in black South Africans is below 10% at 1 year of
age but 70 - 80% in adulthood.,,·,.,15 Whatever the
mechanism, the data indicate that mass vaccination in the
first year of life, by reducing the high incidence of hepatitis
B,'6 might be expected to reduce the prevalence of chronic
hepatitis B, cirrhosis and hepatocellular carcinoma.
The infectiVity of patients with acute or chronic HBV
infection correlates best with the amount of circulating virus,
which may be determined by measuring HBV DNA"
However, for practical purposes persons with HBe antigen
are usually more infectious than those with the
corresponding antibody. Unfortunately traditional views on
the importance of HBe antigen status in predicting both the
progression of disease and infectivity have been challenged
by the identification of HBe antigen-negative mutant viruses,
which behave aggressively despite the lack of this serum
marker in infected individuals.'·
Pre-exposure prophylaxis - vaccination
Plasma-derived and recombinant HBV yeast-derived
vaccines are considered equally safe and effective. Vaccine
is given intramuscularly in the deltoid muscle and repeated
at 1 and 6 months. Administration in the buttock is less
effective and should be avoided. The dose is 20 g per
injection in adults and 10 g in children.
Studies of the plasma-derived vaccine have shown that
among susceptible healthy people who develop anti-HBs
antibodies after the full 3-dose vaccine schedule, protective
efficacy approaches 100%. This landmark study on HBV
vaccine by Szmuness and co-workers also provided data
suggesting that vaccination given after exposure may also
be partially effective.19.20 These data support the concept that
anti-HBs antibody is the protective neutralising antibody and
that vaccine-induced antibody confers protection against
clinically apparent hepatitis B and the development of the
HBs antigen-positive carrier state.
The protective efficacy of vaccination correlates with the
strength of the immune response to the vaccine as
measured by the titre of anti-HBs antibodies" The critical
antibody level above which near-complete protection
against HBV infection is achieved is 10 mU/ml of anti-HBs.
In a study of homosexual men at 5 and 7 years after
vaccination when anti-HBs antibody had fallen below 10
mU/ml, protection against clinical HBV infection persisted."
Revaccination with a single booster dose results in a
dramatic anamnestic response in those who have lost anti-
HBs antibody.23 At present there is no official guideline as to
the timing of booster injections. For adults and children with
normal immune status booster doses are not routinely
recommended within 7 years after vaccination, and routine
serological testing to assess antibody levels is not
necessary during this period. Patients on haemodialysis
appear to be protected only while they display titres over
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10 mU/ml;" the suggested policy is to assess their antibody
titres annually and to give booster doses when levels fall
below this level.
Non-responders are defined as those who fail to develop
protective titres of antibodies despite 4 injections. Various
protocols, including a change from the recombinant vaccine
to the plasma-derived vaccine, have been suggested to
boost immunity in this group, but are of limited efficacy.
Who should be vaccinated?
In developed countries, where the incidence of hepatitis B is
low and largely confined to certain well-defined risk groups,
vaccination schedules were initially targeted at these groups.
Thus the advisory committee on immunisation practices'·6,25
has recommended that the following groups be vaccinated:
People at occupational risk. HBV infection is a major
infectious occupational hazard for health care workers. The
risk of acquiring HBV infection is dependent on the
frequency of percutaneous and mucosal exposure to blood
or blood products. The more likely the worker is to be
exposed to blood or other fluids, the more urgent the
necessity for vaccination. The risk of exposure is often
higher in students than in qualified personnel, and
vaccination should preferably be completed before students
or trainees first come into contact with patients. Subgroups
of staff at special risk include those working in mental
institutions, where the virus may be spread by bites and
assaults as well as by needle-stick injuries. People at lower
risk who should also be vaccinated include those working in
schools or sheltered workshops for the mentally disabled.
Patients at risk. Hepatitis B vaccination is recommended
for susceptible haemodialysis patients. Although
seroconversion rates and anti-HBs titres are lower than
those for healthy persons, for those patients who do
respond, hepatitis B vaccine will protect against HBV
infection and reduce the necessity for frequent serological
screening. Seronegative patients in mental institutions and
special schools appear to be at lower risk than staff
members but may also be vaccinated, as may patients in
day-care programmes, particularly if they are in contact with
aggressive patients who are carriers and may spread the
vinus by biting or scratching.
Recipients of blood products. Patients with clotting
disorders who receive clotting factor concentrates have an
increased risk of HBV infection and should be vaccinated.
Household and sexual contacts of HBV carriers.
Household contacts of HBV carriers are at high risk of HBV
infection. Sexual contacts, including spouses, boyfriends
and girlfriends, appear to be at greatest risk. Condom use
should be advised while vaccination becomes effective.
When HBV carriers are identified, they should be educated
about the condition and its spread, and all household and
sexual contacts should be tested for anti-HBs antibody.
Those who are negative are susceptible and must be
vaccinated.
People in casual contact with carriers in schools and
offices are at minimal risk of HBV infection, and vaccine is
not routinely recommended. At child care centres, HBV
transmission between children or between children and staff
has rarely been documented. Unless special circumstances
that might facilitate transmission exist, for example
behavioural problems such as biting or scratching or
medical conditions such as severe skin disease, vaccination
of children in contact with a carrier is not indicated.
Those at risk of sexual transmission. Sexually active
homosexual and bisexual men should be vaccinated as
soon as possible, regardless of their age. Sexually active
heterosexuals with mUltiple partners and prostitutes are also
at increased risk, and vaccination is recommended for them'
diagnosis of other sexually transmitted diseases should '
prompt consideration of vaccination. Those who are
concurrently HIV-positive should be tested for anti-HBs
antibody response after completion of the vaccine series
since their response may be suboptimal. '
Drug abusers. Those using injectible drugs must be
vaccinated as soon as possible.
Prisoners may be at risk because of drug abuse and
homosexual activity.
International travellers. Vaccination should be
considered for non-immune travellers who plan to stay for
more than 6 months in endemic areas, and for short-term
travellers who are likely to have intimate, and particularly
sexual, contact with local people. Vaccination should begin
at least 6 months before travel to allow for completion of the
full series, but partial vaccination will offer some protection.
Other considerations. In the USA, it is recommended
that children adopted from Africa or Asia should be
screened for HBs antigen; if positive, the adopting family
should be vaccinated. This is of limited applicability in South
Africa which is in itself an endemic area.
In sub-Saharan Africa, where the prevalence of markers of
previous hepatitis B infection exceeds 80%, a different
approach is clearly necessary. Even in the USA, targeted
vaccination has failed to reduce the incidence of hepatitis
B}6 The problem is exemplified by the observation that 90%
of vaccine was administered to one group - health care
workers - who account for less than 5% of the case load.
Groups with higher prevalence, particularly drug abusers,
prostitutes and homosexual men, are far more difficult to
identify and vaccinate before transmission has occurred' in
addition, many cases of hepatitis B do not fall into '
recognised risk groups.
Even in the developed nations one therefore cannot hope
to control the disease by selective vaccination alone.
Although vaccination must be offered to high-risk groups,
universal childhood immunisation appears to offer the only
chance of making an impact on the prevalence of hepatitis
B, and the Global Advisory Group of the Expanded
Programme on Immunisation (EPI) has now called for the
incorporation of hepatitis El vaccination in all national
immunisation programmes, with a target date of 1995 for
endemic areas and 1997 for all others}526
Of course high-risk groups described above remain
candidates for hepatitis B infection as much in South Africa
as elsewhere, and should be considered for vaccination.
Vaccination is clearly desirable for doctors, dentists, nurses,
and students entering these professions. Patients on dialysis
and haemophiliacs should be vaccinated. Family and sexual
contacts of carriers must be tested and vaccinated, as
should the homosexual community.
Age-specific data on the occurrence of hepatitis B and the
prevalence of serological markers of HBV infection indicate
that perinatal transmission of HBV is uncommon in South
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Africa. Further, the incidence of HBV in the first 3 years of life
is very low."'" Hence a national hepatitis B vaccination
programme providing universal coverage by the 3rd year of life
would lead to the control of hepatitis B. Such a programme is
currently being planned for South Africa and its implementation
is imminent, probably in the second half of 1994.
Since there is much higher coverage for vaccines
administered during the first 6 months of life than thereafter,
when mothers may be less motivated to bring their children
for immunisation, early administration of hepatitis B vaccine
is preferable. However, increasing the number of vaccination
visits in order to accommodate hepatitis B vaccination is to
be avoided, since it will lead to lower coverage. Integrating
hepatitis B vaccine into the vaccination schedule currently
being used in South Africa is therefore optimally achieved by
linking it with the polio/OPT schedule of vaccine doses at 3,
41/2 and 6 months. This is the recommendation of the South
African National Advisory Group on Immunisation. The
seroconversion rate with this proposed schedule is only
marginally lower than a 0-, 1- and 6-month schedule. The
timing of booster doses, if necessary, is not clear at present
and needs to be assessed in a cohort of vaccinees who
received this schedule before a recommendation can be
made.
Post-exposure prophylaxis
The risk of infection with hepatitis B may be reduced
dramatically in people exposed to the virus provided that
they are identified, tested and treated promptly. Most such
people fall into one of two groups; health workers who suffer
needle-stick injuries or accidental splashes or spills of blood
or fluids from infected patients, and babies born to mothers
carying the virus. Both passive immunisation with hepatitis B
immune globulin (HBIG) and active immunisation with
recombinant or plasma-derived vaccine are important in
schedules of post-exposure prophylaxis.
HBIG is manufactured from plasma with high titres of anti-
HBs antibody and contains an anti-HBs antibody titre more
than 1 000 times that of conventional IG. Prompt
immunoprophylaxis is necessary because the interval
between exposure and antigenaemia can be as short as 6
days27 and viraemia may develop even earlier. HBIG is
therefore best injected within hours of exposure, but may be
effective even when given within the first few days. Because
its half-life in vivo is 17 - 25 days, a second dose of IG
should be administered 30 days later. The recommended
dose for adults is is 250 - 500 U; most preparations of HBIG
contain 100 U/ml.
Accidental exposure
The protective efficacy of HBIG studied in a variety of post-
exposure settings is of the order of 75%. There is good
evidence that combined active-passive immunisation is
considerably more effective than passive immunisation
alone. In one study of staff in a renal dialysis unit following
needle-stick injury, the risk of transmission of hepatitis B
was 33% with passive immunisation alone, but only 4% with
the combined schedule.2• Contacts given HBIG should
therefore be given hepatitis B vaccine at the same time, the
HBIG and vaccine being given in different sites. The active
vaccine must, however, be given in the deltoid and not the
buttock for maximal efficacy.
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The following protocol is recommended: 5.•
For exposed people who have not previously been
vaccinated, test the serum of the exposed person for anti-
HBs antibody and the serum of the source for HBs antigen.
If the exposed person has seroprotective titres of anti-HBs
antibody, no further therapy is necessary. If a rapid result
cannot be obtained, administer a single intramuscular dose
of HBIG (0,06 ml/kg) within 24 hours of exposure, or as soon
as possible.
Where the source is proved to be HBs antigen-negative,
the source is non-infectious and no immediate further action
is necessary. However, if the exposed person is anti-HBs
antibody-negative, it is wise to commence conventional
vaccination as soon as possible to protect against future
exposure.
Where the source is proved to be HBs antigen-positive,
and the exposed person does not have protective titres of
anti-HBs antibody, HBIG, if not already administered, is
given and active immunisation using an accelerated, 4-dose
schedule is started. The first dose of HBV vaccine is given
intramuscularly at a different site to the HBIG within 7 days
of exposure, and 3 further doses are given at 1, 2 and 6
months. When combined with the vaccine, a second dose of
HBIG at 4 weeks is not required for otherwise healthy
individuals.29
Where the HBs antigen status of the source cannot be
determined, it is wise to assume that it was positive. If the
exposed person is susceptible, administer both HBIG and
the accelerated schedule of HBV vaccine. If it is thought to
be very unlikely that the source was an HBsAg carrier, use of
HBIG may be omitted, but the vaccine should still be given.
For exposed people who have previously been
vaccinated, test the serum of the source for HBs antigen
and the serum of the exposed person for anti-HBs antibody.
Where the source is HBs antigen-positive, and the
exposed person received either full or partial immunisation,
it is necessary to find out whether protective levels of anti-
HBs antibody are still present by determining the titre. If
anti-HBs is adequate, no treatment is indicated. If anti-HBs
titres are below the protective threshold, give HBIG and a
single dose of vaccine at separate sites. Where anti-HBs
antibodies are undetectable, give HBIG as soon as possible
and commence the full accelerated schedule of vaccination.
If levels of anti-HBs antibodies have been tested and
found to be seroprotective within 12 months before
exposure, it is unnecessary to retest them; the patient is
immune and no further action is necessary. Similarly, if it is
known that adequate anti-HBs levels were demonstrated
after vaccination, even if more than 12 months previously, a
single booster dose of vaccine will ensure that levels are
adequate and may be given instead of determining the titres
at this stage. If the exposed person had previously been
vaccinated with 4 or more doses of vaccine but did not
demonstrate protective titres, he or she is a non-responder
who is at risk of infection. Two doses of HBIG (the first as
early as possible, the second a month later) should be given.
If the exposed person had received fewer than 3 doses
but shows adequate levels of anti-HBs antibody, it is
sufficient to complete the course of vaccination. If levels are
inadequate give HBIG (0,06 ml/kg) as soon as possible and
then complete the vaccine schedule.
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Where the source is HBs antigen-negative, no further
action is necessary. People who have not received a full
course of vaccine should complete the course.
Where the source cannot be tested, it is wise to consider
it as positive and continue as outlined above, which will in
any event ensure that the exposed person will be adequately
protected in the event of a further accident. Known vaccine
non-responders should receive HBIG as early as possible; a
second HBIG dose, 1 month later, is optional.
Perinatal exposure
Vertical transmission of HBV from mother to infant during
the perinatal period usually has severe sequelae. Infants
born to HBe antigen-positive mothers have a 70 - 90%
chance of acquiring perinatal HBV infection. It is known that
85 - 90% of infected infants will become chronic HBV
carriers30 and it is estimated that 25% of these carriers will
die from cirrhosis or primary hepatocellular carcinoma.
Infants born to HBsAg-positive, but HBe antigen-negative
mothers have a lower risk of acquiring perinatal infection.
Although prenatal screening of all pregnant woman would
identify those who are at risk, the low incidence of perinatal
transmission in South Africa coupled with the low HBe
antigen prevalence in pregnant women" make antenatal
screening for hepatitis B an unwarranted and cost-
ineffective strategy in this country at present.
Treatment of the infant born to the HBe antigen-positive
mother with HBIG and hepatitis B vaccine is 85 - 95%
effective in preventing the development of the HBV chronic
carrier state. For the prevention of perinatal transmission
from HBe antigen-positive mothers, HBIG in a dose of 200 U
should be given together with active immunisation within 12
hours of birth29 and preferably within the first hour. HBV
vaccine is given at the same time at a separate site and
repeated at 1 and 6 months after the first dose. Breast-
feeding is not contraindicated.
Safety of human serum IG and
hepatitis B hyperimmune globulin
The frequency of adverse reactions is about 1% in recipients
of intramuscular IG. These are generally limited to pain and
tenderness at the injection site. Haematomas are seen
occasionally, especially in patients who are receiving
anticoagulants. The few reported cases of anaphylactic
shock may have been due to inadvertent intravenous
injection. It should also be noted that intravenous
preparations of gamma-globulin are inappropriate for the
prophylaxis of hepatitis. Angioneurotic oedema may also
develop in a few patients. Both the plasma-derived and
recombinant hepatitis B vaccine appear to be extremely
.safe. Of 41 possible adverse neurological events reported
after 850 000 vaccinations with the plasma-derived vaccine,
it was considered that none were causally related to the
vaccine.32
Both immune globulin and HBIG, and indeed the plasma-
derived hepatitis B vaccine, are prepared by methods which
will inactivate retroviruses.33 Transmission of the human
immunodeficiency virus (HIV) has never been reported 34
despite widespread use of these preparations, and they
should never be withheld because of fear of HIV infection.
Hepatitis C (HCV)
Currently patients receiving blood products constitute the
only group at risk of hepatitis C infection, which is readily
recognisable and hence potentially amenable to pre-
exposure prophylaxis. Some early work suggested that
administration of immune serum globulin before transfusion
might reduce the incidence of post-transfusional non-A,
non-B hepatitis.35.36 However, the need for this crude form of
pre-exposure prophylaxis has fallen away with the
introduction of routine screening of blood donors for HCV.
There are likewise no data to support the use of IG for post-
exposure prophylaxis, and it is not recommended. 37
Hepatitis 0 (HDV)
Passive immunisation for the prevention of HDV infection is
not available, and anti-HDV has not been shown to be a
neutralising antibody. However, the disease is eminently
preventable, since HDV cannot survive except in the
presence of co-infecting HBV. Measures to prevent initial
infection with HBV will therefore be equally effective against
hepatitis D. Hepatitis D is not a problem in South Africa. In
countries where it is encountered, it is largely a disease of
intravenous drug abusers. Vaccination of this group against
hepatitis B will substantially diminish the pool of HDV in the
community; universal vaccination against hepatitis B may
eventually eradicate it.
Hepatitis E (HEV)
There is no evidence to suggest that immune globUlin will
prevent hepatitis E infection. Although immune globulin .
prepared in developing countries where the disease is
endemic is likely to have specific antibodies, a report from
India indicates that immune serum globulin is useless in
preventing transmission of the disease.36 In any case no
vaccine is available, and the only measures recommended
for the prevention of HEV infection are those relating to
good personal hygiene and the prevention of contamination
of food and water supplies.
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